Literature DB >> 16756967

Cancer chemopreventive and anti-inflammatory activities of chemically modified guar gum.

Amira M Gamal-Eldeen1, Hassan Amer, Wafaa A Helmy.   

Abstract

Guar gum (G) is a simple characterized branched polysaccharide, which is frequently used in food industries. We prepared the gum C-glycosylated derivative (GG), and its sulphated derivative (SGG), aiming to characterize their cancer chemopreventive, and anti-inflammatory properties. Estimation of cancer chemopreventive activity, specifically anti-initiation, including the modulation of carcinogen metabolism and the antioxidant capacity, revealed that GG was a potent anti-initiator, where it inhibited not only the carcinogen activator enzyme, cytochrome P450 1A (CYP1A), but also induced the carcinogen detoxification enzymes glutathione-S-transferases (GSTs), while SGG inhibited both CYP1A and GSTs. SGG was an effective radical scavenger than GG against hydroxyl, peroxyl, and superoxide anion radicals. GG and SGG were found to modulate the macrophage functions into an anti-inflammatory pattern. Thus, both enhanced the macrophage proliferation and phagocytosis of fluorescein isothiocyanate (FITC)-zymosan; however, they also inhibited strongly the nitric oxide generation and tumor necrosis factor-alpha secretion in lipopolysaccharide (LPS)-stimulated RAW macrophage 264.7. Unexpectedly, both GG and SGG dramatically inhibited the binding affinity of FITC-LPS to RAW 264.7, as indicated by flow cytometry analysis. GG and SGG exhibited a significant anti-proliferative activity against human hepatocellular carcinoma cells (Hep G2), and only SGG was specifically cytotoxic for human breast carcinoma cells (MCF-7), but neither was significantly cytotoxic for human lymphoblastic leukemia cells (1301). SGG led to a major disturbance in cell cycle phases of Hep G2 cells as indicated by concomitant arrest in S- and G2/M-phases, a disturbance that was associated with an induced cell death as a result of necrosis, but not apoptosis in both GG- and SGG-treated cells. Taken together, the modified gums could be used as an alternative of G in health food industries to provide cancer prevention in risk populations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16756967     DOI: 10.1016/j.cbi.2006.03.010

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  6 in total

1.  Incomplete degradation products of galactomannan from Sesbania cannabina modulated the cecal microbial community of laying hens.

Authors:  Yuheng Tao; Ting Wang; Caoxing Huang; Chenhuan Lai; Zhe Ling; Yanmin Zhou; Qiang Yong
Journal:  J Anim Sci       Date:  2022-04-01       Impact factor: 3.338

2.  Cosmeceutical Effects of Galactomannan Fraction from Arenga pinnata Fruits In vitro.

Authors:  Soegianto Ali
Journal:  Pharmacognosy Res       Date:  2017 Jan-Mar

3.  Ulva lactuca polysaccharides prevent Wistar rat breast carcinogenesis through the augmentation of apoptosis, enhancement of antioxidant defense system, and suppression of inflammation.

Authors:  Gamal-Eldein F Abd-Ellatef; Osama M Ahmed; Eman S Abdel-Reheim; Abdel-Hamid Z Abdel-Hamid
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-02-27

Review 4.  Polymeric plant-derived excipients in drug delivery.

Authors:  Carien E Beneke; Alvaro M Viljoen; Josias H Hamman
Journal:  Molecules       Date:  2009-07-16       Impact factor: 4.411

5.  Antiviral and Antioxidant Activities of Sulfated Galactomannans from Plants of Caatinga Biome.

Authors:  Márcia Maria Mendes Marques; Selene Maia de Morais; Ana Raquel Araújo da Silva; Naiara Dutra Barroso; Tadeu Rocha Pontes Filho; Fernanda Montenegro de Carvalho Araújo; Ícaro Gusmão Pinto Vieira; Danielle Malta Lima; Maria Izabel Florindo Guedes
Journal:  Evid Based Complement Alternat Med       Date:  2015-07-14       Impact factor: 2.629

6.  Immunomodulatory effect of an isolated fraction from Tinospora crispa on intracellular expression of INF-γ, IL-6 and IL-8.

Authors:  Walaa Najm Abood; Iman Fahmi; Mahmood Ameen Abdulla; Salmah Ismail
Journal:  BMC Complement Altern Med       Date:  2014-06-27       Impact factor: 3.659

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.